High Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026
Rhea-AI Summary
High Tide (NASDAQ/TSXV: HITI) announced that majority-owned German subsidiary Remexian Pharma showcased its exclusive German medical cannabis distribution partnerships at Mary Jane Berlin 2026, held June 11–14 in Berlin.
Remexian highlighted premium Canadian brands and its expanding pharmacy network in Germany's growing medical cannabis market.
Positive
- None.
Negative
- None.
News Market Reaction – HITI
In the Jun 17 session, HITI declined 5.95%, reflecting a notable negative market reaction. Argus tracked a trough of -2.1% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 15 | Q2 2026 earnings | Positive | +12.0% | Record revenue and EBITDA with improved margins and positive net income. |
| Jun 15 | Credit facilities | Positive | -2.6% | C$40MM senior secured credit facilities approval from Bank of Montreal. |
| Jun 15 | Retail acquisition | Positive | -2.6% | Agreement to acquire Northern Helm’s four Ontario cannabis stores. |
| Jun 10 | Store openings | Positive | -1.7% | Announcement of new Canna Cabana locations in Welland and Calgary. |
| Jun 03 | Earnings date set | Positive | -2.9% | Scheduling Q2 2026 results release and related webcast; stock options grant. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news skewed positive (record revenue, German growth, new stores, credit facilities), but price reactions often dipped on expansion/financing headlines, while strong earnings drew a double‑digit gain.
Over the last few weeks, High Tide has reported record Q2 2026 revenue and adjusted EBITDA, highlighted rapid growth at German subsidiary Remexian, and secured $40 million in senior secured credit facilities. It also pursued expansion via new Canna Cabana stores and the planned Northern Helm acquisition, lifting its Canadian footprint toward 228 locations. Despite generally positive fundamentals, several expansion and financing announcements saw modest negative price reactions, while the earnings release coincided with a strong +12% move.
Key Terms
medical cannabis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
At the event, Remexian featured medical cannabis products from Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals and Castle Rock Farms, highlighting its growing portfolio of exclusive brand distribution agreements and connecting these Canadian brands directly with pharmacies, healthcare professionals, patients and other key stakeholders across
"The response we received at Mary Jane Berlin reinforces what we are seeing across the German market: patients and healthcare professionals are actively seeking differentiated, high-quality cannabis products backed by trusted brands. Through Remexian, we are bringing some of
"By continuously broadening our product offering and strengthening relationships across the supply chain, we are positioning Remexian to capture an even larger share of one of the world's most attractive medical cannabis markets. This is another example of how High Tide is leveraging its Canadian strengths to build a globally diversified cannabis platform with multiple avenues for long-term growth," Added Mr. Grover
ABOUT HIGH TIDE
High Tide, Inc. is the leading community-grown, retail-forward cannabis enterprise engineered to unleash the full value of the world's most powerful plant. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. High Tide (HITI) is uniquely-built around the cannabis consumer, with wholly-diversified and fully-integrated operations across all components of cannabis, including:
Retail: Canna Cabana™ is the largest cannabis retail chain in Canada, with 228 domestic and 1 international location. The Company's Canadian bricks-and-mortar operations span British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario, holding a growing
Medical Cannabis Distribution: Remexian Pharma GmbH is a leading German pharmaceutical company, with a
High Tide consistently moves ahead of the currents, having been named one of Canada's Top Growing Companies by the Globe and Mail's Report on Business in 2025 for the fifth consecutive year and was recognized as a top 50 company by the TSX Venture Exchange (the "TSXV") in 2022, 2024 and 2025. High Tide was also ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023. To discover the full impact of High Tide, visit www.hightideinc.com. For investment performance, don't miss the High Tide profile pages on SEDAR+ and EDGAR.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
CONTACT INFORMATION
Media Inquiries
Omar Khan
Chief Communications and Public Affairs Officer
High Tide Inc.
omar@hightideinc.com
403-770-3080
Investor Inquiries
Vahan Ajamian
Capital Markets Advisor
High Tide Inc.
vahan@hightideinc.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain "forward-looking information" and "forward-looking statements within the meaning of applicable securities legislation. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking statements herein include, but are not limited to, statements regarding: the growth potential for Remexian and the ability to capture further market share. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed under the heading "Non-Exhaustive List of Risk Factors" in Schedule A to our current annual information form, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at www.sedarplus.ca and www.sec.gov, which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/high-tides-german-subsidiary-remexian-pharma-showcases-exclusive-canadian-medical-cannabis-brand-partnerships-at-mary-jane-berlin-2026-302802470.html
SOURCE High Tide Inc.